AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
Try a sample question
Select a question to fill the search bar, then submit it or edit it first.
AI can make mistakes. Verify answers against the original sources before relying on them.
fenbendazole 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| anthelminthics, tiabendazole derivatives | 4536 | 43210-67-9 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
Antinematodal benzimidazole used in veterinary medicine.
|
Drug dosage:
None
ADMET properties:
None
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | 3.946 | High | 0.84 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.769 | High | 0.84 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 72.111 | 10^-6 cm/s | High | 0.84 |
| dh-clint | Dog hepatocyte intrinsic clearance | 15.031 | uL/min/10^6 cells | High | 0.84 |
| dppb | Dog plasma protein binding (% unbound) | 1.010 | % | High | 0.84 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 2.450 | % | High | 0.84 |
| herg | hERG pIC50 | 4.696 | pIC50 | High | 0.84 |
| hh-clint | Human hepatocyte intrinsic clearance | 12.972 | uL/min/10^6 cells | High | 0.84 |
| hlm-clint | Human liver microsomal intrinsic clearance | 34.041 | uL/min/mg protein | High | 0.84 |
| hppb | Human plasma protein binding (% unbound) | 0.630 | % | High | 0.84 |
| kinase-safety-class | ACVR2A,ACVR2B,ALK,AURKA,AXL,BRAF,BTK,CAMK2B,CAMK2D,CDK5,CDK9,CSF1R,DDR1,DYRK1B,EIF2AK3,ERBB2,FLT3,GRK2,GSK3B,ITK,JAK1,JAK2,MAP3K1,MAP3K21,MAP3K7,MAP4K1,MAPK10,MAPK7,MAPK9,MARK4,MTOR,NTRK2,PDK2,PDK4,PIK3CB,PIK3CD,PIK3CG,PIM2,PRKDC,SGK1,SIK2,SIK3,STK33,TEK,TTK | 45 | |||
| kinase-selectivity-class | ACVR2B,AURKA,CDK9,CSF1R,DDR1,EGFR,ERBB2,FLT3,GRK2,JAK1,MAP2K6,MAP3K1,MAP3K21,MAPK7,MARK4,PDK4,SIK2,SIK3,STK33 | 19 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 1.346 | High | 0.84 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 74.302 | High | 0.84 | |
| mppb | Mouse plasma protein binding (% unbound) | 1 | High | 0.84 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 1.250 | High | 0.84 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 2.330 | % | High | 0.84 |
| rh-clint | Rat hepatocyte intrinsic clearance | 28.379 | uL/min/10^6 cells | High | 0.84 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 13.870 | % | High | 0.84 |
| rppb | Rat plasma protein binding (% unbound) | 0.530 | % | High | 0.84 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 1.146 | uM | High | 0.84 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | P02CA06 | ANTIPARASITIC PRODUCTS, INSECTICIDES AND REPELLENTS ANTHELMINTICS ANTINEMATODAL AGENTS Benzimidazole derivatives |
| MeSH PA | D000871 | Anthelmintics |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000969 | Antinematodal Agents |
| MeSH PA | D000977 | Antiparasitic Agents |
| CHEBI has role | CHEBI:35443 | anthelminthic drug |
| CHEBI has role | CHEBI:35444 | antinematodal drug |
Related Drugs by ATC class:
P02CA Benzimidazole derivatives 6 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
None
🐶 Veterinary Drug Use
| Species | Use | Relation |
|---|---|---|
| Cattle | Removal and control of lungworm, Dictyocaulus viviparus | Indication |
| Cattle | Removal and control of stomach worm (adults) | Indication |
| Cattle | Removal and control of brown stomach wormd, Ostertagia ostertagi | Indication |
| Cattle | Removal and control of stomach worms (adults and 4th-stage larvae) | Indication |
| Cattle | Removal and control of barberpole worms, H placei | Indication |
| Cattle | Removal and control of small stomach worms, Trichostrongylus axei | Indication |
| Cattle | Removal and control of intestinal worms (adults and 4th-stage larvae) | Indication |
| Cattle | Removal and control of hookworm, Bunostomum phlebotomum | Indication |
| Cattle | Removal and control of threadnecked intestinal worms, Nematodirus helvetianus | Indication |
| Cattle | Removal and control of small intestinal worms, Cooperia punctata | Indication |
| Cattle | Removal and control of bankrupt worms, Trichostrongylus colubriformis | Indication |
| Cattle | Removal and control of nodular worm, Oesophagostomum radiatum | Indication |
| Cattle | Removal and control of barberpole worms, H placei | Indication |
| Cattle | Removal and control of small intestinal worms, C oncophora | Indication |
| Goats | Removal and control of stomach worms, Haemonchus contortus (adults) | Indication |
| Goats | Removal and control of stomach worms, Teladorsagia circumcincta | Indication |
| Horses | Control of large strongyles, Strongylus edentatus | Indication |
| Horses | Control of small strongyles, Cyathostomum species | Indication |
| Horses | Control of pinworms, Oxyuris equi | Indication |
| Horses | Control of ascarids (Parascaris equorum) | Indication |
| Horses | Control of large strongyles, S equinus | Indication |
| Horses | Control of large strongyles, S vulgaris | Indication |
| Horses | Control of small strongyles, Cylicocyclus species | Indication |
| Horses | Control of small strongyles, Cylicostephanus species | Indication |
| Horses | Control of small strongyles, Triodontophorus species | Indication |
🐶 Veterinary products
| Product | Applicant | Ingredients |
|---|---|---|
| Panacur Suspension 10% | Intervet Inc. | 1 |
| Panacur Granules 22.2% | Intervet Inc. | 1 |
| panacur, safe-guard | Intervet Inc. | 1 |
| Panacur C (OTC), Safe-Guard Canine (OTC), Panacur Granules 22.2% (Rx) | Intervet Inc. | 1 |
| Safe-Guard , Panacur | Intervet Inc. | 1 |
| Safe-Guard | Intervet Inc. | 1 |
| Panacur 10% Paste, Safe-Guard | Intervet Inc. | 1 |
| Safe-Guard Type A Medicated Article | Intervet Inc. | 1 |
| Safe-Guard | Intervet Inc. | 1 |
| SAFE-GUARD plus LINCOMIX | Intervet Inc. | 2 |
| BMD / Safe-Guard | Zoetis Inc. | 2 |
| Panacur Plus | Intervet Inc. | 3 |
| Safe-Guard AquaSol | Intervet Inc. | 1 |
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 10.61 | acidic |
| pKa2 | 13.2 | acidic |
| pKa3 | 3.71 | Basic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Mitogen-activated protein kinase 14 | Kinase | IC50 | 5.50 | DRUG MATRIX | |||||
| Beta-lactamase 1 | Enzyme | IC50 | 5.22 | DRUG MATRIX |
External reference:
| ID | Source |
|---|---|
| D04140 | KEGG_DRUG |
| N0000166935 | NUI |
| CHEBI:77092 | CHEBI |
| CHEMBL37161 | ChEMBL_ID |
| 3395 | INN_ID |
| DB11410 | DRUGBANK_ID |
| 621BVT9M36 | UNII |
| 4325 | RXNORM |
| NOCODE | MMSL |
| 013514 | NDDF |
| 96134008 | SNOMEDCT_US |
| C0015821 | UMLSCUI |
| D005273 | MESH_DESCRIPTOR_UI |
| 3334 | PUBCHEM_CID |
| 621BVT9M36 | INXIGHT DRUGS |
Pharmaceutical products:
| Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
|---|---|---|---|---|---|---|---|---|
| Fenbendazole 222 MG | HUMAN OTC DRUG LABEL | 1 | 85130-100 | CAPSULE | 299.35 mg | ORAL | unapproved drug other | 7 sections |
| FENBENDAZOLE Oral Dewormer | HUMAN OTC DRUG LABEL | 1 | 87276-263 | PASTE | 100 mg | ORAL | OTC Monograph Drug | 7 sections |
| PREPAKU FENBENDAZOLE Canine Dewormer | HUMAN OTC DRUG LABEL | 1 | 87276-264 | GRANULE | 222 mg | ORAL | OTC Monograph Drug | 7 sections |